Isotretinoin and the risk of depression in patients with acne vulgaris: A case-crossover study

Journal of Clinical Psychiatry

Volumn 69, Issue 4, 2008, Pages 526-532

  Azoulay, Laurent ^a,b   Blais, Lucie ^a,c   Koren, Gideon ^d,e   LeLorier, Jacques ^a   Bérard, Anick ^a,b  

^a Department of Pharmacy ^*  (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ISOTRETINOIN; MONOAMINE OXIDASE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ACNE VULGARIS; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DYSTHYMIA; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR;

EID: 44849131178     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0403     Document Type: Article

References (48)

1. Rubinow DR, Peck GL, Squillace KM, et al. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987;17:25-32
2. Layton AM. Psychosocial aspects of acne vulgaris. J Cutan Med Surg 1998;2(suppl 3):19-23
3. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999;140:273-282
4. Ng CH, Tam MM, Celi E, et al. Prospective study of depressive symptoms and quality of life in acne vulgaris patients treated with isotretinoin compared to antibiotic and topical therapy. Australas J Dermatol 2002;43:262-268
5. Ferahbas A, Turan T, Esel E, et al. A pilot study evaluating anxiety and depressive scores in acne patients treated with isotretinoin. J Dermatolog Treat 2004;15:153-157
6. Hazen PG, Carney JF, Walker AE, et al. Depression - a side effect of 13-cis-retinoic acid therapy. J Am Acad Dermatol 1983;9:278-279
7. Bigby M, Stern RS. Adverse reactions to isotretinoin: a report from the Adverse Drug Reaction Reporting System. J Am Acad Dermatol 1988;18:543-552
8. Gatti S, Serri F. Acute depression from isotretinoin. J Am Acad Dermatol 1991;25:132
9. Jensen JB. Isotretinoin (Roaccutan) and depression [Danish]. Ugeskr Laeger 1998;160:7290-7291
10. Citrome L. Safety of Accutane with possible depression. Postgrad Med 1998;104:38
11. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000;136:1231-1236
12. Hersom K, Neary MP, Levaux HP, et al. Isotretinoin and antidepressant pharmacotherapy: a prescription sequence symmetry analysis. J Am Acad Dermatol 2003;49:424-432
13. Friedman T, Wohl Y, Knobler HY, et al. Increased use of mental health services related to isotretinoin treatment: a 5-year analysis. Eur Neuropsychopharmacol 2006;16:413-416
14. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001;45:515-519
15. Wysowski DK, Pitts M, Beitz J. Depression and suicide in patients treated with isotretinoin. N Engl J Med 2001;344:460
16. Wooltorton E. Accutane (isotretinoin) and psychiatric adverse effects. CMAJ 2003;168:66
17. O'Donnell J. Overview of existing research and information linking isotretinoin (Accutane), depression, psychosis, and suicide. Am J Ther 2003;10:148-159
18. Hoffman-Roche Laboratories Ltd. Accutane TM Roche® (Isotretinoin) 10-mg and 40-mg capsules. [Product monograph]. Mississauga, Ontario, Canada
19. Important safety information on Accutane [Dear Healthcare Professional Letter]. Health Canada, 2001. Available at: http://www.hc-sc.gc.ca/dhpmps/ alt_formats/hpfb-dgpsa/pdf/medeff/accutane_hpc-cps_e.pdf. Accessed Apr 12, 2006
20. Régie de l'assurance maladie du Québec. Statistiques annuelles. Quebec, Canada: Government of Quebec; 1997
21. World Health Organization. International Classification of Diseases, Ninth Revision. Geneva, Switzerland: World Health Organization; 1977
22. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009
23. Tamblyn R, Reid T, Mayo N, et al. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000;53:183-194
24. Levy AR, Mayo NE, Grimard G. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. Am J Epidemiol 1995;142:428-436
25. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-153
26. Duke EE, Guenther L. Psychiatric reaction to the retinoids. Can J Dermatol 1993;5:467
27. Middelkoop T. Roaccutane (isotretinoin) and the risk of suicide: case report and a review of the literature and pharmacovigilance reports. J Pharm Pract 1999;12:374-378
28. Wert S. Identification and management of oral isotretinoin use inconsistent with product labeling. Manag Care Interface 2003;16:41-43, 55
29. Perkins AJ, Kroenke K, Unutzer J, et al. Common comorbidity scales were similar in their ability to predict health care costs and mortality. J Clin Epidemiol 2004;57:1040-1048
30. Wang PS, Schneeweiss S, Glynn RJ, et al. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann Epidemiol 2004;14:296-303
31. Aubin S, Lorette G, Muller C, et al. Massive isotretinoin intoxication. Clin Exp Dermatol 1995;20:348-350
32. Kunynetz RA. A review of systemic retinoid therapy for acne and related conditions. Skin Therapy Lett 2004;9:1-4
33. Physicians Desk Reference. 55th ed. Product labeling for isotretinoin. Montvale, NJ: Medical Economics Company, Inc.; 2001
34. Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003;4:833-842
35. Cotterill JA, Cunliffe WJ. Suicide in dermatological patients. Br J Dermatol 1997;137:246-250
36. Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999;140:672-676
37. Yazici K, Baz K, Yazici AE, et al. Disease-specific quality of life is associated with anxiety and depression in patients with acne. J Eur Acad Dermatol Venereol 2004;18:435-439
38. Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J Am Acad Dermatol 2002;46:505-509
39. Azoulay L, Oraichi D, Bérard A. Patterns and utilization of isotretinoin for acne from 1984 to 2003: is there need for concern? Eur J Clin Pharmacol 2006;62:667-674
40. Hudson CG. Socioeconomic status and mental illness: tests of the social causation and selection hypotheses. Am J Orthopsychiatry 2005;75:3-18
41. Bremner JD. Does isotretinoin cause depression and suicide? Psychopharmacol Bull 2003;37:64-78
42. Restak RM. Pseudotumor cerebri, psychosis, and hypervitaminosis A. J Nerv Ment Dis 1972;155:72-75
43. Silverman AK, Ellis CN, Voorhees JJ. Hypervitaminosis A syndrome: a paradigm of retinoid side effects. J Am Acad Dermatol 1987;16:1027-1039
44. O'Donnell J. Polar hysteria: an expression of hypervitaminosis A. Am J Ther 2004;11:507-516
45. Sakai Y, Crandall JE, Brodsky J, et al. 13-cis Retinoic acid (Accutane) suppresses hippocampal cell survival in mice. Ann N Y Acad Sci 2004;1021:436-440
46. Sheline YI, Sanghavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999;19:5034-5043
47. O'Reilly KC, Shumake J, Gonzalez-Lima F, et al. Chronic administration of 13-cis-retinoic acid increases depression-related behavior in mice. Neuropsychopharmacology 2006;31:1919-1927
48. Bremner JD, Fani N, Ashraf A, et al. Functional brain imaging alterations in acne patients treated with isotretinoin. Am J Psychiatry 2005;162:983-991